- Teladoc is moving beyond its single-visit roots with new launchOver two decades ago, Teladoc built its business around quick doctor visits that didn't happen in person. Now, it's saying that the model of one-off virtual appointments is no longer enough. The…Endpoints · 1d ago↗ source
- Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clearEli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug…Fierce Biotech · 1d ago↗ source
- Roche Diagnostics growth remains muted amid China headwindsRoche’s Diagnostics division continues to battle growth headwinds, notching a 3% increase in sales.